Skip to main content
Funded Studies

Mark Braughler, PhD

Vice President, Therapeutics at RheoGene Inc.

Mark Braughler, PhD is currently Vice President, Therapeutics at RheoGene. Prior to joining RheoGene, Dr. Braughler was Vice President, Business Development - Healthcare for Icoria, Inc., a publicly traded biotechnology company located in Research Triangle Park, NC. Dr. Braughler joined Paradigm Genetics in March 2004 as part of its acquisition of TissueInformatics. Inc, a Pittsburgh-based life sciences software development and drug discovery company where he had served as Sr. Vice President, Business Development from 2000-2004, and Acting COO since 2003. From 1998 to 2000, Dr. Braughler was President and CEO of Argonex Inc. (Upstate Biotechnology), a biotechnology company based in Charlottesville, VA, where he was instrumental in the creation of RheoGene as a joint venture between Rohm and Haas and Argonex. From 1995 to 1998, he was Vice President, Business Development of Pharmacia and Upjohn, a global pharmaceutical company formed through the merger of Pharmacia Corporation and The Upjohn Company in 1995. From 1989 to 1995, he served as Director of Acquisition Review, Research Contracts, Competitive Intelligence and Intellectual Property for The Upjohn Company. Dr. Braughler was a Senior Research Scientist for The Upjohn Company from January 1982 to August 1989 where he led global drug discovery and development efforts in central nervous system trauma and ischemia. Dr. Braughler was Associate Professor of Pharmacology with tenure at the Northeastern Ohio Universities College of Medicine from June 1979 to December 1982. Dr. Braughler received his PhD in pharmacology in 1976 from the University of Pittsburgh School of Medicine and completed an NIH post-doctoral fellowship in Clinical Pharmacology at the University of Virginia School of Medicine from 1977 to 1979. Dr. Braughler has authored more than 90 peer-reviewed publications and is a recipient of the Fred Kagan Lead Finding Award as well as the Lifetime Achievement in Science and Medicine Award from the Upjohn Company.

Associated Grants

  • Development and Optimization of a Regulatable Gene Switch for Gene Therapies of Parkinson’s Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.